Researchers in Maryland unleash synthetic DNA

Researchers at the J. Craig Venter Institute have created the largest man-made DNA structure to date, putting them one step closer to producing a completely synthetic organism, according to the institute.

The work, published online by Dan Gibson, Ph.D. in the journal Science, raises hopes for benefits like new drugs and pollution scarfing micro-organisms while spooking some with visions of biological warfare and patent wielding corporations controlling all future forms of synthetic life.

The researchers chemically created DNA fragments in the lab then used homologous recombination (a process that cells use to repair damage to their chromosomes) in the yeast Saccharomyces cerevisiae to rapidly build the entire bacterial chromosome from large sub-assemblies, according to the press release. "This extraordinary accomplishment is a technological marvel that was only made possible because of the unique and accomplished JCVI team," said president and founder J. Craig Venter.

Venter dismisses concerns that what JCVI is really creating is the "microbesoft" of synthetic life. His team has long been concerned with the societal issues surrounding its work and has undergone"significant ethical review" by experts who founds no reason why work should cease "as long as the scientists involved continued to engage public discussion," according to the JCVI Web site.

Critics remain unimpressed. "Venter is claiming bragging rights to the world's longest length of synthetic DNA, but size isn't everything. The important question is not 'how long?' but 'how wise?'" said Jim Thomas in a bio-watchdog article castigating Venter.

"While synthetic biology is speeding ahead in the lab and in the marketplace, societal debate and regulatory oversight is stalled and there has been no meaningful or inclusive discussion on how to govern synthetic biology in a safe and just way. In the absence of democratic oversight profiteering industrialists are tinkering with the building blocks of life for their own private gain."

Next step would be to insert the synthetic DNA into living cells and hope it becomes the world's first artificially created, self-replicating organism.

Online Gene Mapping

Two rival companies have launched novel genetic services which, for a price tag of $1000 (Rs. 40,000), will allow people to have their genomes scanned, delivering them personal information about their ancestry, some personal disease risks and other inherited traits.
The first - called deCODEme - was launched by Icelandic company deCODE Genetics on 16 November. Customers send a cheek swab in the post from which DNA can be extracted and analysed for 'over one million variants in your genome', says the website. This is achieved by comparing the customer's genome with a database of thousand's of people's genomes in search for single letter changes - known as SNPs - which can act as signposts for disease risk or other inherited traits. Within 2-3 weeks customers can expect to have access to their personal genome profile via a password-protected online account.
The second - called 23andMe, a reference to the number of pairs of chromosomes in the human genome - was launched on 19 November by a start-up company based in California's Silicon Valley. Similarly, customers send a saliva sample in the post from which DNA can be extracted and analysed for 'nearly 60,000 datapoints on your genome', says the website. 23andMe
co-founder Anne Wojcicki is married to Google co-founder Sergey Brin, who is also a major funder of the venture.
Both websites emphasise that they are not medical-diagnostic services, instead marketing themselves as providers of genetic information. 23andMe even promotes the novelty of being able to 'connect with other 23andMe customers through sharing features', raising the prospect that a kind of gene-based social networking service might evolve, like MySpace or FaceBook.
Some critics have raised concerns over the potential value of a growing body of genetic information to a biotech or insurance company, particularly in light of the fact that 23andMe intends to share anonymised information with outside groups for the purpose of research. While both companies have stressed that they take confidentiality very seriously, promising to accept customers anonymously if specified, there are further concerns that insurance companies might mount legal pressure on such
companies in order to force information disclosure. 'Will they stoutly defend privacy if sued by insurers?' asks The Economist, also worried that any personal genetic information shared with doctors in the US could inadvertently make its way into the hands of insurers via medical records.
Although there are obvious benefits to be gained from the availability of personal genome services, there are also legitimate concerns that such services could cause unnecessary anxiety for some. 'I would think twice before spitting into that vial', says author Nicholas Carr, writing in the Guardian (UK).

MAVERICK GENOME SCIENTIST UNVEILS HIS GENETIC CODE

The scientist who lead the private effort to sequence the human genome has revealed his own complete genetic make-up. The race to decode the human genome may not be entirely over: the loser has come up with a new approach that may let him prevail in the end. In 2003, a US government-financed consortium of academic centers announced it had completed the human genome, fending off a determined challenge from the biologist J. Craig Venter. The consortium’s genome comprised just half the DNA contained in a normal cell, and the DNA used in the project came from a group of people from different racial and ethnic backgrounds. But the loser in the race, Dr. Venter, could still have the last word. In a paper published recently, his research team is announcing that it has decoded a new version of the human genome that some experts believe may be better than the consortium’s. Called a full, or diploid genome, it consists of the DNA in both sets of chromosomes, one from each parent, and it is the normal genome possessed by almost all the body’s cells. And the genome the team has decoded belongs to just one person: Dr. Venter.
Dr. Venter’s race with the consortium began in 1998 when he spotted a quicker method of decoding the human genome. He tried to wrest this rich scientific prize from his academic rivals by co-founding a genome-decoding company called Celera. By June 2000, the two sides were neck and neck preparing a draft sequence of the genome. But in January 2002, Dr. Venter was abruptly fired as president of Celera. The consortium went on to claim victory when it announced its completion of the genome the next year. But the consortium’s genome, though immensely useful to biologists, was full of gaps and only complete in the sense that it was the best that could be done with existing technology. Dr. Venter has spent the last five years and an extra $10 million of his institute’s money in improving the draft genome he prepared at Celera. That genome was based mostly on his own DNA, and the new diploid version is entirely so. His critics may accuse him of an egocentricity of considerable dimension, but by analyzing his own genome he has sidestepped the problems of privacy and consent that could have arisen with other people’s DNA when he made the whole sequence publicly available, as he is doing now.
Like James Watson, the co-discoverer of DNA, whose genome is also being decoded, Dr. Venter believes strongly in making individual DNA sequences public to advance knowledge and hasten the era of personalized genomic medicine.
The unveiling of J. Craig Venter's genome in the open access journal PloS Biology marks the first time that the complete DNA sequence of an individual has been published. In 2001, Venter's company Celera published a version of the human genome that was based on information from himself and four other individuals. At the same time, the publicly-funded Human Genome Project consortium released a consensus human genome, based on DNA samples from over 100 people.
The latest study shows that the amount of genetic variation between individuals is 5-7 times greater than previously suspected. In addition to the expected 3.2 million single DNA 'letter' changes known as SNPs, Venter's genome has nearly a million other variations, which involve small sections of missing, duplicated or 'flipped around' DNA. 'This is the first time that anyone has had an accurate representation of how much variation there is in a human genome', said co-author Stephen W. Scherer of Toronto University.
Commenting on the findings, Venter said that: 'each time we peer deeper into the human genome we uncover more valuable insight into our intricate biology', adding that 'only with additional sequencing of more individual
genomes will we garner a full understanding of how our genes influence our lives'. He also revealed that the results show he has a moderate risk of developing Alzheimer's disease, saying 'there are two groups of people out there, the half that really want to know about themselves and the half that's afraid to know because of all this genetic deterministic nonsense', adding 'knowing what is there will do nothing to change what is already going on in my body'.
The new genome sequence, dubbed HuRef, was pieced together using the 'whole genome shotgun' method previously used by Celera. However, several organisations are now working on faster, cheaper methods that will eventually enable the genome of many more people to be sequenced. DNA pioneer James Watson is the only other person currently having his genome decoded.